Document is current
Any future updates will be listed below
-
Authors
- License Information
-
More Information
Article History
First Online: 25 April 2025
Competing interests
: C.A.M. has financial interests in Flashpoint Therapeutics; M.M. has financial interests in ModuMab Therapeutics; and N.A. has financial interests in SpideRx, all of which could potentially benefit from the outcomes of this research.
